|
Jan 22
|
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
|
|
Jan 22
|
Ionis says rare disease drug succeeds in late-stage HAE study
|
|
Jan 19
|
Insider Sell: EVP CLO & General Counsel Patrick O'Neil Sells 7,744 Shares of Ionis ...
|
|
Dec 30
|
EVP CLO & General Counsel Patrick O'Neil Sells 20,825 Shares of Ionis Pharmaceuticals Inc
|
|
Dec 24
|
Ionis Pharmaceuticals Inc EVP, Chief Scientific Officer C Bennett Sells 22,613 Shares
|
|
Dec 21
|
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
|
|
Dec 21
|
CORRECTED-UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug
|
|
Dec 20
|
12 Most Promising Gene Editing Stocks According to Hedge Funds
|
|
Dec 20
|
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 19
|
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
|
|
Dec 18
|
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
|
|
Dec 7
|
Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?
|
|
Dec 1
|
Ionis Pharmaceuticals (NASDAQ:IONS) shareholders have earned a 23% return over the last year
|
|
Oct 26
|
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Aug 30
|
Ionis to present at upcoming investor conferences
|